Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00272909 · ClinicalTrials.gov registry record · Phase 2

Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)

A Phase 2 study, sponsored by Daiichi Sankyo.

Terminated
Registry status
Phase 2
Development phase
43
Enrollment target

NCT00272909: Clinical Trial Phase 2 study, sponsored by Daiichi Sankyo.

NCT00272909 is a Phase 2 study that was terminated before completion, run by Daiichi Sankyo. The registered enrollment target is 43 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00272909, a Phase 2 study, was terminated before completion, sponsored by Daiichi Sankyo.

TERMINATED
Registry status
Phase 2
Development phase
43 participants
Enrollment target

Study Summary

This research study is designed to evaluate the safety, tolerability, and efficacy of SUN N4057 (piclozotan) in subjects with acute ischemic stroke within 9 hours of the onset of symptoms.

Interventions

  • DRUG placebo
  • DRUG piclozotan low dose
  • DRUG piclozotan high dose

Trial Details

FieldValue
Enrollment Target 43 participants
Start Date 2004-09
Est. Completion 2007-01
Phase Phase 2
Daiichi Sankyo

236 total trials

Why NCT00272909 stopped before completion

NCT00272909 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).

The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.

NCT00272909 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00272909 about?

NCT00272909 is a clinical study titled "Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)". This research study is designed to evaluate the safety, tolerability, and efficacy of SUN N4057 (piclozotan) in subjects with acute ischemic stroke within 9 hours of the onset of symptoms.

What is the current status of trial NCT00272909?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2004-09. Estimated completion is 2007-01.

What interventions are being tested in trial NCT00272909?

The interventions under investigation include: placebo (DRUG), piclozotan low dose (DRUG), piclozotan high dose (DRUG).

Who is sponsoring clinical trial NCT00272909?

This trial is sponsored by Daiichi Sankyo, which has 236 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00272909's enrollment target sits among peer trials

43 1332nd of 2000 higher than 662 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03726359 · 43 participants · Phase 1

    Phase I Study of Fractionated Stereotactic Radiation Therapy

  • NCT03850418 · 43 participants · Phase 2

    Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

  • NCT04144023 · 43 participants · Phase 1

    A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

  • NCT04176718 · 43 participants · Phase 2

    Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00272909, the US trial registry maintained by the National Library of Medicine. NCT00272909 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.